Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$38.37 +3.3%	$40.28	$26.20 ▼ $63.50	$1.77B	1.47	609,479 shs	881,770 shs
IMCR Immunocore	$35.74 +1.7%	$32.95	$23.15 ▼ $41.54	$1.80B	0.77	342,786 shs	157,445 shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
TARS Tarsus Pharmaceuticals	$41.55 +2.4%	$42.12	$20.08 ▼ $57.28	$1.75B	0.8	685,271 shs	476,901 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-4.48%	+2.00%	-16.50%	+15.92%	-24.79%
IMCR Immunocore	-0.42%	+5.62%	+1.36%	+26.12%	-10.95%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	-2.29%	+2.24%	-0.76%	-17.84%	+44.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.0648 of 5 stars	3.5	3.0	0.0	0.0	2.5	4.2	0.0
IMCR Immunocore	1.4303 of 5 stars	3.3	0.0	0.0	0.0	2.1	2.5	0.0
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	1.8379 of 5 stars	3.5	0.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	158.01% Upside
IMCR Immunocore	2.55	Moderate Buy	$58.89	64.77% Upside
PFNX Pfenex	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	60.45% Upside

Current Analyst Ratings Breakdown

Latest PFNX, APGE, IMCR, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $115.00
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/8/2025	IMCR Immunocore	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $86.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
IMCR Immunocore	$310.20M	5.79	N/A	N/A	$7.20 per share	4.96
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	$182.95M	9.54	N/A	N/A	$5.87 per share	7.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.43	N/A	N/A	N/A	-6.48%	-5.86%	-2.09%	8/6/2025 (Estimated)
PFNX Pfenex	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest PFNX, APGE, IMCR, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.08	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.41	N/A	N/A	N/A	$95.81 million	N/A
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	15.82	15.82
IMCR Immunocore	1.03	6.36	6.31
PFNX Pfenex	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
IMCR Immunocore	84.50%
PFNX Pfenex	N/A
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
IMCR Immunocore	10.40%
PFNX Pfenex	N/A
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

PFNX, APGE, IMCR, and TARS Headlines

Recent News About These Companies

William Blair Issues Pessimistic Estimate for TARS Earnings

July 16 at 6:02 AM | marketbeat.com

William Blair Has Bearish Estimate for TARS FY2026 Earnings

July 16 at 2:01 AM | americanbankingnews.com

What is William Blair's Estimate for TARS FY2026 Earnings?

July 15 at 8:23 AM | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Consensus PT from Analysts

July 15 at 2:17 AM | americanbankingnews.com

Tarsus Pharmaceuticals Stock Price, Quotes and Forecasts

July 13 at 10:38 PM | benzinga.com

Hot Tick Summer Is Here. Here’s What You Need to Know and How to Stay Safe

July 12, 2025 | gizmodo.comG

Grant GrossMendelsohn LLC Sells 26,143 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 12, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Analysts

July 12, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Sells 12,401 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 5, 2025 | marketbeat.com

Tarsus Pharmaceuticals Inc Ordinary Shares - Morningstar

July 2, 2025 | morningstar.comM

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Lisanti Capital Growth LLC

June 29, 2025 | marketbeat.com

Tarsus Pharmaceuticals Becomes Oversold (TARS)

June 19, 2025 | nasdaq.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

June 17, 2025 | marketbeat.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

Tarsus to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 27, 2025 | benzinga.com

Tarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with Xdemvy

May 21, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFNX, APGE, IMCR, and TARS Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$38.37 +1.23 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$38.26 -0.11 (-0.29%)

As of 05:56 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Immunocore NASDAQ:IMCR

$35.74 +0.59 (+1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$35.74 +0.00 (+0.01%)

As of 04:31 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)

As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Tarsus Pharmaceuticals NASDAQ:TARS

$41.55 +0.97 (+2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$41.72 +0.18 (+0.42%)

As of 06:01 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time